Daniels I R, Fisher S E, Heald R J, Moran B J
Pelican Cancer Foundation, North Hampshire Hospital, Basingstoke RG24 9NA, UK.
Colorectal Dis. 2007 May;9(4):290-301. doi: 10.1111/j.1463-1318.2006.01116.x.
The current optimal management of locally advanced rectal cancer has evolved from surgical excision followed by postoperative therapy in patients with involved margins, to an increasing use of a preoperative strategy to 'down-stage and/or down-size' the tumour. This treatment strategy is based on the relationship of the tumour to the mesorectal fascia, the optimal surgical circumferential resection margin that can be achieved by total mesorectal excision. We have reviewed the recent evidence for this strategy.
An electronic literature search using PubMed identified articles on the subject of rectal cancer between January 2000 and December 2005. The search was limited to English language publications with secondary references obtained from key articles. Articles published in high impact factor journals formed the basis of the review, together with articles related to national programmes on the management of rectal cancer. This does lead to a selection bias, particularly as the articles identified had a European bias.
The UK NHS Cancer Plan has outlined the basis for the multidisciplinary team (MDT) management of rectal cancer. Advances in preoperative assessment through accurate staging and the recognition of the importance of the relationship of the tumour to the mesorectal fascia has allowed the selection of patients for a preoperative strategy to down-size/down-stage the tumour if this fascial layer is involved or threatened. Improvements in the quality of surgical resection through the acceptance of the principle of total mesorectal excision have ensured that optimal surgery remains the cornerstone to successful treatment. Further refinements of the MDT process strive to improve outcome. Accurate radiological staging, optimal surgery and detailed histopathological assessment together with consideration of a preoperative neoadjuvant strategy should now form the basis for current treatment and future research in rectal cancer.
局部晚期直肠癌目前的最佳治疗方案已从对切缘阳性患者进行手术切除并术后治疗,演变为越来越多地采用术前策略来“降期和/或缩小”肿瘤。这种治疗策略基于肿瘤与直肠系膜筋膜的关系,以及通过全直肠系膜切除所能达到的最佳手术环周切缘。我们回顾了支持该策略的近期证据。
通过使用PubMed进行电子文献检索,确定了2000年1月至2005年12月间关于直肠癌主题的文章。检索仅限于英文出版物,并从关键文章中获取二次参考文献。发表在高影响因子期刊上的文章以及与国家直肠癌管理计划相关的文章构成了综述的基础。这确实导致了选择偏倚,尤其是因为所确定的文章存在欧洲偏向。
英国国民健康服务体系癌症计划概述了直肠癌多学科团队(MDT)管理的基础。通过准确分期以及认识到肿瘤与直肠系膜筋膜关系的重要性,术前评估取得了进展,这使得如果该筋膜层受累或受到威胁,可以选择患者采用术前策略来缩小肿瘤大小/降低肿瘤分期。通过接受全直肠系膜切除原则,手术切除质量得到了提高,确保了最佳手术仍然是成功治疗的基石。MDT流程的进一步完善致力于改善治疗结果。准确的影像学分期、最佳手术、详细的组织病理学评估以及对术前新辅助策略的考虑,现在应该构成直肠癌当前治疗和未来研究的基础。